Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:PYRGF NASDAQ:RKTO NYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.19-9.2%$1.22$0.88▼$5.48$34.06M0.56122,014 shs77,026 shsPYRGFPyroGenesis Canada$0.19+14.2%$0.27$0.12▼$0.53$39.14M0.1959,788 shs33,907 shsRKTORocket One Inc. Common Stock$1.12-24.7%$0.91$0.49▼$2.45$33.04M0.8920.75 million shs22.26 million shsTOVXTheriva Biologics$0.30-1.0%$0.30$0.16▼$0.86$10.36M1.115.87 million shs7.53 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.55%-9.03%+24.76%+3.15%-21.56%PYRGFPyroGenesis Canada+0.42%-9.32%-52.33%-60.69%-53.64%RKTORocket One Inc. Common Stock+11.28%-24.87%+124.28%+43.69%+12.12%TOVXTheriva Biologics+26.08%+8.67%-4.63%+75.23%-42.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.19-9.2%$1.22$0.88▼$5.48$34.06M0.56122,014 shs77,026 shsPYRGFPyroGenesis Canada$0.19+14.2%$0.27$0.12▼$0.53$39.14M0.1959,788 shs33,907 shsRKTORocket One Inc. Common Stock$1.12-24.7%$0.91$0.49▼$2.45$33.04M0.8920.75 million shs22.26 million shsTOVXTheriva Biologics$0.30-1.0%$0.30$0.16▼$0.86$10.36M1.115.87 million shs7.53 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma+1.55%-9.03%+24.76%+3.15%-21.56%PYRGFPyroGenesis Canada+0.42%-9.32%-52.33%-60.69%-53.64%RKTORocket One Inc. Common Stock+11.28%-24.87%+124.28%+43.69%+12.12%TOVXTheriva Biologics+26.08%+8.67%-4.63%+75.23%-42.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ARKTORocket One Inc. Common Stock 2.00Hold$5.00348.43% UpsideTOVXTheriva Biologics 3.00Buy$1.00229.16% UpsideCurrent Analyst Ratings BreakdownLatest TOVX, PYRGF, RKTO, and ABVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/8/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/1/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/31/2026TOVXTheriva Biologics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$1.003/25/2026RKTORocket One Inc. Common Stock D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K60.67N/AN/A$0.52 per share2.29PYRGFPyroGenesis Canada$9.14M4.28N/AN/A($0.01) per share-18.90RKTORocket One Inc. Common StockN/AN/AN/AN/A$0.40 per shareN/ATOVXTheriva BiologicsN/AN/AN/AN/A$0.46 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-62.46%-39.99%8/18/2026 (Estimated)PYRGFPyroGenesis Canada-$21.12M-$0.04N/AN/AN/A-115.14%N/A-60.81%N/ARKTORocket One Inc. Common Stock-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%N/ATOVXTheriva Biologics-$23.74M-$33.06N/AN/AN/AN/A-178.29%-59.96%N/ALatest TOVX, PYRGF, RKTO, and ABVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A5/15/2026Q1 2026RKTORocket One Inc. Common Stock-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/5/2026Q1 2026TOVXTheriva BiologicsN/A-$0.05N/A-$0.05N/A$0.30 million3/27/2026Q4 2025RKTORocket One Inc. Common Stock-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/12/2026Q4 2025TOVXTheriva BiologicsN/A$1.30N/A$1.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ARKTORocket One Inc. Common StockN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.120.12PYRGFPyroGenesis CanadaN/A0.600.50RKTORocket One Inc. Common StockN/A3.393.39TOVXTheriva Biologics0.111.631.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%PYRGFPyroGenesis Canada0.03%RKTORocket One Inc. Common Stock7.08%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%PYRGFPyroGenesis Canada47.68%RKTORocket One Inc. Common Stock6.92%TOVXTheriva Biologics0.67%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3026.00 million21.06 millionNot OptionablePYRGFPyroGenesis Canada90207.07 million96.34 millionNo DataRKTORocket One Inc. Common Stock422.32 million20.78 millionNot OptionableTOVXTheriva Biologics2033.74 million33.51 millionNot OptionableTOVX, PYRGF, RKTO, and ABVC HeadlinesRecent News About These CompaniesTheriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer ResearchJune 11 at 8:00 AM | globenewswire.comTheriva Biologics Faces Quorum Issue Delaying Warrant VoteJune 5, 2026 | tipranks.comAlliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)May 7, 2026 | theglobeandmail.comTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial ResultsMay 5, 2026 | globenewswire.comTheriva Biologics (TOVX) Stock Soars 63% on Promising Pancreatic Cancer Trial ResultsApril 21, 2026 | blockonomi.comTheriva Biologics stock surges on AACR cancer trial dataApril 21, 2026 | investing.comTheriva Biologics Highlights Positive VCN-01 Pancreatic Cancer DataApril 20, 2026 | theglobeandmail.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual ...April 19, 2026 | finance.yahoo.comTherivaâ„¢ Biologics anuncia la próxima presentación de datos adicionales del ensayo clÃnico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026April 18, 2026 | globenewswire.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual MeetingApril 17, 2026 | globenewswire.comTheriva Biologics (TOVX) price target decreased by 37.50% to 2.55April 10, 2026 | msn.comMaxim Group upgrades Theriva Biologics (TOVX)April 1, 2026 | msn.comTheriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal AdenocarcinomaMarch 23, 2026 | markets.businessinsider.comTheriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial ResultsMarch 12, 2026 | markets.businessinsider.comTheriva Biologics licenses SYN-020 to Rasayana Therapeutics for multiple indicationsFebruary 19, 2026 | thepharmaletter.comTTheriva Biologics, Inc.: Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple IndicationsFebruary 18, 2026 | finanznachrichten.deTheriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple IndicationsFebruary 18, 2026 | markets.businessinsider.comTheriva Biologics Faces Delay in Warrant Approval MeetingFebruary 12, 2026 | tipranks.comTheriva Biologics, Inc.: Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026February 3, 2026 | finanznachrichten.deTheriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026February 3, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOVX, PYRGF, RKTO, and ABVC Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.19 -0.12 (-9.16%) Closing price 04:00 PM EasternExtended Trading$1.24 +0.05 (+4.54%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.PyroGenesis Canada NASDAQ:PYRGF$0.19 +0.02 (+14.20%) As of 03:55 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada.Rocket One Inc. Common Stock NASDAQ:RKTO$1.12 -0.37 (-24.66%) As of 04:00 PM EasternHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.Theriva Biologics NYSEAMERICAN:TOVX$0.30 0.00 (-1.04%) Closing price 04:10 PM EasternExtended Trading$0.29 -0.01 (-4.87%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
